Former Medical Lead across Genentech's immunology portfolio: Rituxan, Actemra, Gazyva, and pipeline immunology.
Former Head of Clinical Development at Alladapt Immunotherapeutics, then Medical Launch Lead at Neurocrine Biosciences.
Saw the same identification gap at every stage: first-in-human design, launch, and label expansion, across immunology and rare disease.
Repeat founder. Prior company backed by Khosla Ventures.
Former SVP of Health Plan Business at Blue Cross Blue Shield of Michigan.
Former Board member at Blue Health Intelligence, Blue Venture Fund, and Consortium Health Plans.
Saw the same gap from the other side of the system.
Owns Aisomer's partnerships and the data agreements behind them.